Concept and System Design of RateControlled Drug Delivery

Concept and System Design of Rate-Controlled Drug Delivery System Introduction and Background 1

Topics n n Definitions Classifications of CR Systems q n n n Rate control, physical form Design considerations Routes of administration Review of mass transfer 2

Definition of Controlled Release n A system that: q q q Delivers an agent at a controlled rate for an extended time Might localize drug action by spatial placement near where it is needed Might target drug action by using techniques to deliver drug to a particular cell type 3

Controlled Release Agents n In nature (? ) q q q Oxygenation of blood Transport of nutrients and waste through cell membranes Transport and evaporation of water (sweat) to control body temperature n Engineered systems (? ) q q q Drugs Biocides Fragrances 4

Definitions Sustained release, sustained action, controlled release, extended action, timed release dosage forms are the terms used to identify drug delivery systems that are designed to achieve a prolonged therapeutic effect by continuously releasing medication over an extended period of time after the administration of single dose. The term “Controlled release” has become associated with those systems from which therapeutic agents may be automatically delivered at predefined rates over a long period of time. But, there are some confusion in terminology between “Controlled release” & “Sustained release” 5

Sustained Release : ü The term sustained release has been constantly used to describe a pharmaceutical dosage formulated to retard the release of a therapeutic agent such that its appearance in the systemic circulation is delayed &/or prolonged & its plasma profile is sustained in duration. Controlled Release : ü This term on the other hand, has a meaning that goes beyond the scope of sustained drug action. ü It also implies a predictability & reproducibility in the drug release kinetics, which means that the release of drug ingredient from a controlled delivery system proceeds at a rate profile that is not only predictable kinetically, but also reproducible from one unit to another. 6

Controlled Release vs. Sustained Release n Controlled drug delivery q q Well-characterized and reproducible dosage form Controls entry to the body according to the specifications of the required drug delivery profile n n rate and duration of delivery are designed to achieve desired concentration Sustained Release q q Release of drug is extended in time Rate and duration are not designed to achieve a particular profile. 7

Controlled Release vs. Conventional n Conventional Controlled Release Systemic Drug Concentration Toxic q q Effective q Ineffective Time n CR q q Drug Concentration rises quickly to effective level. Effective concentration is maintained for extended time q Periodic administration Non-specific administration High systemic concentrations can be toxic, causing side effects or damage to organs Low concentrations can be ineffective 8

Disadvantages of Conventional Delivery (Brainstorm) n n n Inconvenient Difficult to monitor Careful calculation necessary to prevent overdosing Large amounts of drug can be “lost” when they don’t get to the target organ Drug goes to non-target cells and can cause damage Expensive (using more drug than necessary) 9

Advantages of Controlled (Brainstorm) Release n n Reproducible rate, prolonged delivery Less frequent administration q q n n Better patient compliance Increased convenience Reduced side effects because effective C is maintained Targeting can eliminate damage to non-target organs Less drug used Re-patenting without new drug development 10

Challenges to Controlled Release n n Cost of formulation – preparation and processing Fate of controlled release system if not biodegradable Biocompatibility Fate of polymer additives, e. g. , plasticizers, stabilizers, antioxidants, fillers 11

An ideal controlled drug delivery system is the one which delivers the drug at a predetermined rate, locally or systematically for a specified period of time. 12

Polymer Systems for Controlled Release n Classified by q q Type of device Rate controlling mechanism Types Mechanisms Matrix Diffusion Through a matrix or membrane Reservoir/Membrane Chemical reaction – erosion or cleavage (Hybrids) Osmotic Pumps Solvent activation Osmotic pump or polymer swelling 13

Classification Based on their technical sophistication : n Rate preprogrammed drug delivery system n Activation-modulated drug delivery system n Feedback-regulated drug delivery system n Site targeting drug delivery system 14

Rate preprogrammed drug delivery system In this group , the release of drug molecule from the system has been preprogrammed at specific rate profile. 1. 2. 3. They can be classified as Polymer membrane permeation-controlled drug delivery system Polymer matrix diffusion-controlled drug delivery system Microreservior partition-controlled drug delivery system 15

1. Polymer membrane permeationcontrolled drug delivery system In this type, drug is totally or partially encapsulated within drug reservoir. Its drug release surface is covered by a ratecontrolling polymeric membrane having a specific permeability. Drug reservoir may exist in solid, suspension or solution form. 16

The rate of drug release is defined by, Q t = Km/r Ka/m Dd. Dm x CR Km/r Dmhd + Ka/m Ddhm Where, Km/r & Ka/m = partition coefficient of the drug molecule from reservoir to rate controlling membrane & from membrane to aq. Layer respectively. Dd & Dm = diffusion coefficient of rate controlling membrane & aqueous diffusion layer respectively. hm & hd = thickness of rate controlling membrane & aqueous diffusion layer respectively. CR – drug conc. In reservoir compartment. 17

Release of drug molecules is controlled by : Partition coefficient of the drug molecule. Diffusivity of the drug molecule. The thickness of the rate controlling membrane. 18

2. Polymer matrix diffusioncontrolled drug delivery system In this type, drug reservoir is prepared by homogeneously dispersing drug particle in rate controlling polymer matrix from either a lipophilic or a hydrophilic polymer. The drug dispersion in the polymer matrix is accomplished by either, 1) blending therapeutic dose of drug with polymer or highly viscous base polymer, followed by cross linking of polymer chains. 2) mixing drug solid with rubbery polymer at elevated temp. 19

The rate of the drug release from this system, Q = (2 ACRDp)1/2 t Where, Q/t 1/2 - rate of release of drug A – initial drug loading dose in the polymer matrix CR – drug solubility in polymer Dp – diffusivity of drug in polymer matrix 20

Release of drug molecule is controlled by Loading dose Polymer solubility of drug Drug diffusivity in polymer matrix. Ex. Nitro-Dur : n Nitro-Dur is a transdermal system contains nitroglycerin in acrylic-based polymer adhesives with a resinous cross-linking agent to provide a continuous source of active ingredient. 21

It is designed for application on to intact skin for 24 hrs to provide a continuous transdermal infusion of nitroglycerin at dosage rate of 0. 5 mg/cm 2/day for the treatment of angina pectoris. 22

3. Microreservior partitioncontrolled drug delivery system In this type, drug reservoir is fabricated by micro dispersion of an aqueous Suspension of drug in biocompatible polymer to form homogeneous dispersion. Depending upon the physicochemical properties of drugs & desired rate of drug release, the device can be further coated with a layer of biocompatible polymer to modify the mechanism & the rate of drug release. 23

The rate of drug release is defined by, ( ] ( [ d. Q = Dp. Ddm. Kp n. Sp – Dl. Sl(1 -n) 1 + 1 kl Km dt h Dphd + Ddhpm. Kp l Where, n = the ratio of drug conc. At the inner edge of the interfacial barrier over the drug solubility in the polymer matrix. m = a/b, a – ratio of drug conc. In the bulk of elution solution over drug solubility in the same medium. b – ratio of drug conc. At the outer edge of the polymer coating membrane over drug solubility in the same polymer. 24

Kl, Km & Kp = partition coefficient for the interfacial partitioning of the drug from the liquid compartment to the polymer matrix, from the polymer matrix to the polymer-coating membrane & from the polymer coating membrane to the elution solution respectively. Dl, Dp & Dd = diffusivities of the drug in the lipid layer surrounding the drug particle, the polymer coating membrane enveloping the polymer matrix, & the hydrodynamic diffusion layer surrounding the polymer coating membrane with the thickness hl, hp & hd. Sl & Sp = solubilities of the drug in the liquid compartments & in the polymer matrix, respectively. 25

Release of drug molecules from this type of system can follow either a dissolution or a matrix diffusion controlled process depending upon the relative magnitude of Sl & Sp. Release of drug molecule is controlled by, Partition coefficient Diffusivity of drug Solubility of drug 26

Activation modulated drug delivery system n In this group of controlled release drug delivery system, the release of drug molecules from the delivery system is activated by some physical, chemical, or biochemical process and/or by energy supplied externally. 27

Based on nature of the process or type of energy used they can be classified into 1. Physical means a. Osmotic pressure-activated DDS b. Hydrodynamic pressure-activated DDS c. Vapor pressure-activated DDS d. Mechanically activated DDS e. Magnetically activated DDS f. Sonophoresis activated DDS g. Iontophoresis activated DDS h. Hydration-activated DDS 28

2. Chemical means a. p. H- activated DDS b. Ion- activated DDS c. Hydrolysis- activated DDS 3. Biochemical means a. Enzyme- activated DDS b. Biochemical- activated DDS 29

a. Osmotic controlled activated drug delivery system. In this type, drug reservoir can be either solution or solid formulation contained within semi permeable housing with controlled water permeability. The drug is activated to release in solution form at a constant rate through a special delivery orifice. The rate of drug release is modulated by controlling the gradient of osmotic pressure. 30

For the drug delivery system containing a solution formulation, the intrinsic rate of drug release is defined by, Q P w Am ( π – π ) = s e t hm For the drug delivery system containing a solid formulation, the intrinsic rate of drug release is defined by, Q P w Am ( πs – πe ) Sd = t hm 31

Where, Q/t - rate of drug release Pw - permiability of semipermiable housing Am -effective S. A. of semipermiable housing hm - thickness of semipermiable housing ( ps - pe) – differential osmotic pressure between the drug delivery system with osmotic pressure ps & the environment with osmotic presure pe. Sd – aqueous solubility of the drug contained in the solid formulation. 32

Matrix Systems n Drug is physically blended with the polymer q n Dissolved or dispersed This is the simplest and cheapest device At t=0 At time t Polymer matrix contains uniformly dissolved or dispersed drug Drug is being released by some rate-controlling mechanism 33

Reservoir Systems n n With or without a rate-controlling membrane Geometric Form q q Microbead – thin polymer coating around particles or droplets Microtube – polymeric hollow fiber Microbeads Microtube 34

The Osmotic Pump Reservoir containing drug Rigid semipermeable membrane Osmotic agent Flexible impermeable wall 35

Rate Control: Diffusion Polymer film (membrane) Membrane System Drug Time 0 Drug dissolved or dispersed in polymer Time t Drug surrounded by polymer film or membrane Matrix System Time 0 Drug is distributed uniformly throughout polymer Time t Adapted from Langer, Science, 249, 1990 36

Rate Control: Chemical Reaction Drug dissolved or dispersed in polymer Degradation of polymer Time t Time 0 polymer backbone Time 0 drug Time t water or enzyme Cleavage of drug from polymer backbone Adapted from Langer, Science, 249, 1990 37

Biodegradable Systems n n Implants for release of anticancer drugs Lupron Depot® q q q n Injectable microspheres Once per month injecton Prostrate cancer, fertility treatment, early puberty Malaria vaccine 38

Rate Control: Solvent Activation Swollen Polymer from which drug has been released Drug dissolved in polymer Swelling allows drug to migrate more easily Time 0 Time t Drug dispersed in polymer Pores permit release Time 0 Time t Osmotic pressure causes water to penetrate, forming pores and releasing drug Adapted from Langer, Science, 249, 1990 39

p. H- activated drug delivery system This type of chemically activated system permits targeting the delivery of drug only in the region with selected p. H range. It fabricated by coating the drug-containing core with a p. H – sensitive polymer combination. For instances, a gastric fluid labile drug is protected by encapsulating it inside a polymer membrane that resist the degradative action of gastric p. H. 40

In the stomach, coating membrane resists the action of gastric fluid (p. H<3) & the drug molecule thus protected from acid degradation. After gastric emptying the DDS travels to the small intestine & intestinal fluid (p. H>7. 5) activates the erosion of the intestinal fluid soluble polymer from the coating membrane. This leaves a micro porous membrane constructed from the intestinal fluid insoluble polymer, which controls the release of drug from the core tablet. The drug solute is thus delivered at a controlled manner in the intestine by a combination of drug dissolution & pore-channel diffusion. 41

Design Considerations n Basic components q q n Active agent Polymer design considerations (? ) q Physical properties n n q q q Glass transition temperature Diffusion characteristics Compatibility with active Stability – must not decompose in storage Biocompatibility of polymer and degradation products Ease of formulation and fabrication Mechanical properties are stable when drug is added Cost 42

Design considerations n Agent q Physicochemical properties n n n Stability Solubility Partitioning Charge Protein binding propensity 43

Design Considerations n n Route of delivery Target sites q q n Desired site for efficacy Sites to avoid to minimize side effects Type of therapy q Acute or chronic – rate and duration n n e. g. , 1 yr contraceptive implant vs. antibiotic for acute infection Patient condition q q Cognative ability and memory Physical condition – ambulatory, bedridden, etc. 44

Routes of Administration for CR n Parenteral – outside GI tract q Usually refers to injectables n n Subcutaneous Intramuscular Intraperitoneal Intravenous n Advantages q n Bypasses some routes of metabolic clearance Disadvantages (? ) q q Painful Inconvenient 45

Routes of Administration n Oral q Most common route n n n q Easy to formulate and manufacture Patient compliance is generally good Inexpensive dosage form Tricky due to environment of GI tract n n n p. H degradation Enzymatic degradation Intestinal motility – affects residence time q n Single patient and patient-to-patient variations Absorption limitations in stomach 46

Routes of Administration n Buccal/ Sublingual q q q n n Thin mucous membrane Rich blood supply Mild p. H ~6. 0 Rectal q q Nasal q q q Easy administration Rapid absorption Bypasses certain clearance routes q n No p. H or enzymatic degradation as in oral (+) More effective than buccal or sublingual for some drugs (+) Limited absorption (-) Pulmonary q Large S. A. for absorption 47

Routes of Administration n Transdermal q q q n Accessible organ, large surface area Avoid first pass metabolism Avoid GI incompatibility of drugs Good patient compliance Transport across skin can be a challenge Ocular q q q Localized delivery for eye disorders Good absorption for many drugs Loss of drug in tears 48